What changed for Chronic Kidney Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Chronic Kidney Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 356 to 361 (+5)
- Late-stage (Phase 3) trials 35 to 37 (+2)
- Trials on record 3,414 to 3,488 (+74)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Chronic Kidney Disease in July 2026. Voxsanity tracks 2 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 152 trials tracked for Chronic Kidney Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05834738 · results posted 20 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05834738) enrolled 54 people in total — 27 in each group. It tested a medicine called atrasentan against a placebo (a dummy treatment with no active ingredient) in a "crossover" design, meaning participants took one treatment for a period, had a break, then switched to the other. The main thing being measured was the change in protein levels in the urine — specifically a measure called UPCR (the ratio of protein to creatinine in urine collected over 24 hours). High protein in the urine can be a sign of kidney problems, so...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05254002 · results posted 13 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05254002) enrolled 818 people across three groups: one group took both finerenone and empagliflozin together (the combination), one group took finerenone plus a dummy pill (placebo) in place of empagliflozin, and one group took empagliflozin plus a dummy pill in place of finerenone. The trial was primarily measuring a value called UACR — a urine test that shows how much of a protein called albumin is leaking into the urine, which doctors use as a marker of kidney stress in people with type 2 diabetes and chronic kidney dis...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05213624 · results posted 12 January 2026
According to the results reported on ClinicalTrials.gov, this trial looked at three different doses of an investigational medicine called BI 764198 (20 mg, 40 mg, and 80 mg) compared to a placebo (a dummy treatment with no active ingredient) in people with a kidney condition. A total of 67 people were enrolled across the four groups. The main thing the trial was measuring was a protein-to-creatinine ratio in urine — essentially, how much protein was leaking into the urine over 24 hours, which is a marker used to monitor certain kidney conditions. Specifically, the trial tracked whether partici...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03608033 · results posted 9 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03608033) enrolled 181 people in the OMS721 group and 179 people in the placebo group during the treatment period. The trial was measuring changes in the amount of protein leaking into the urine over 24 hours (known as proteinuria — a marker that doctors monitor in certain kidney conditions), as well as changes in how well the kidneys were filtering blood over time. The main focus was on participants who had higher levels of protein in their urine at the start of the study (2 grams or more per day). The reported data show...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05027074 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05027074) enrolled 506 people across three groups: 171 received a higher dose of the investigational drug MK-2060 (20 mg), 167 received a lower dose (6 mg), and 168 received a placebo (an inactive treatment used for comparison). Participants all had an arteriovenous graft — a surgically created connection used for kidney dialysis — and the trial was primarily measuring how often these grafts became blocked by a blood clot (a condition called thrombosis) over time. The reported data shows that for the primary outcome — the...
-
NCT05571605 · results posted 20 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05571605) involved 11 people in total — 5 in an Exercise Training group and 6 in a Stretching group. All 11 participants completed the trial with no drop-outs. The trial was measuring how blood pressure changes in the body relate to blood flow changes in the brain — specifically in a large brain artery called the middle cerebral artery. Two things were measured: a "phase" value (which reflects the timing difference between blood pressure and brain blood flow changes) and a "gain" value (which reflects how much brain blood...
-
NCT05284656 · results posted 11 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05284656) enrolled 80 people in total, split evenly into four groups of 20: one group received folic acid, one received pentoxifylline, one received both folic acid and pentoxifylline together, and one was a control group. All 80 participants completed the study with no drop-outs. The trial was looking at changes in certain blood measurements — specifically a substance called creatinine (a marker used to assess kidney function) and ferritin (a marker related to iron storage in the body) — over a period of six months. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04616612 · results posted 23 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04616612) enrolled 22 people in total — 10 in the "SystemCHANGE™" group and 12 in the "Attention Control" group (a comparison group that received a different level of engagement). The trial was measuring how well people took their medications as prescribed, and also gathered information about how acceptable and credible participants found the program. By the end of the study, 4 of the 10 people in the SystemCHANGE™ group and 9 of the 12 in the Attention Control group completed the trial. The reported data shows that the m...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04994522 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04994522) involved 14 participants in total — 8 people with end-stage renal disease (ESRD, meaning their kidneys had stopped working and they required dialysis) and 6 healthy participants. The trial was measuring how the body absorbs, processes, and clears a drug called belzutifan under different conditions: in people with ESRD both before and after a dialysis session, and in healthy individuals. All participants who started each phase of the trial completed it. The reported data shows the following for the key measuremen...
-
NCT03602261 · results posted 30 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03602261) enrolled 44 people in total — 33 took a weekly capsule called CTAP101 at a dose of 900 micrograms, and 11 took a placebo (a dummy capsule with no active ingredient). Of those who started, 25 in the CTAP101 group and 8 in the placebo group completed the study. The trial was measuring two main things in the blood: levels of a form of vitamin D called 25-hydroxyvitamin D (25D), and levels of a hormone called iPTH (intact parathyroid hormone), which is linked to how the body manages calcium and vitamin D. It also tra...
-
NCT03819153 · results posted 20 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03819153) enrolled 3,533 participants in total — 1,767 received semaglutide and 1,766 received a placebo (an inactive look-alike treatment). The trial was measuring kidney-related outcomes in people over a period of roughly four and a half years. The main thing researchers were tracking was how many participants experienced a serious worsening of kidney function — defined as a combination of events including a large, lasting drop in how well the kidneys filter blood (known as eGFR, a measure of kidney filtering ability), k...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03631290 · results posted 3 February 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a "deprescribing" programme — that is, a structured approach to reducing or stopping certain medicines that may be less suitable for older adults. A total of 41 patients aged 55 and over were approached about taking part, along with 7 healthcare providers (clinicians). The study identified 85 people from medical records who were potentially eligible, and of the 41 patients who were approached, 17 agreed to go ahead with deprescribing. The reported data shows that 15 deprescribing events occurred through one approach...
-
NCT04515849 · results posted 17 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04515849) enrolled 248 participants across five groups: three groups received different doses of an investigational medicine called cotadutide (100 micrograms, 300 micrograms, or 600 micrograms), one group received a placebo (an inactive treatment), and one group received an already-approved medicine called semaglutide. The trial was primarily measuring changes in something called UACR — a urine test that looks at the ratio of two proteins, which is commonly used to assess kidney health in people with diabetes — after 14 w...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04626427 · results posted 16 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 people who were fitted with the WavelinQ™ EndoAVF System — a device used to create an arteriovenous fistula (AVF), which is a surgically created connection between an artery and a vein that can be used for kidney dialysis. The trial was measuring safety (specifically, whether participants experienced serious unwanted events linked to the device or procedure) and effectiveness (how often additional procedures were needed to maintain or support use of the AVF). It is important to note that the trial was ended early,...
-
NCT04571619 · results posted 13 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04571619) compared two groups of people with pain: one group received a programme called Pain Coping Skills Training (PCST) — a structured approach to learning mental and behavioural strategies for managing pain — and the other group received their usual care. A total of 643 people started the trial (319 in the PCST group and 324 in the usual care group), and the study tracked them across two phases. The main thing being measured was how much pain interfered with participants' daily lives, using a standard questionnaire ca...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02532621 · results posted 1 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 158 people who all received a device called the Venous InterGraft Connector (VIG) — a connector used when placing an arteriovenous (AV) graft, which is a surgically created loop under the skin that allows patients to be connected to a dialysis machine. The trial was measuring how well the graft stayed open and usable for dialysis over time, how quickly it could first be used, and what events occurred along the way. Of the 158 people who started, 132 completed the study, with 26 not completing it (the reasons were not...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04736628 · results posted 4 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 261 adults across four groups: three groups received different doses of a medicine called avenciguat (1 mg, 2 mg, or 3 mg, each taken three times a day), and one group received a placebo (a dummy treatment with no active ingredient). The trial ran for 20 weeks and was mainly measuring changes in a kidney marker called the urine albumin-to-creatinine ratio, or UACR — a measure of how much of a protein called albumin is leaking into the urine, which can indicate how the kidneys are functioning. Most participants complet...
-
NCT00645658 · results posted 26 August 2024
According to the results reported on ClinicalTrials.gov, this trial involved two groups of participants: nine people with chronic kidney disease and eight people without kidney disease (the control group). The study was measuring body composition and physical health in the chronic kidney disease group, specifically looking at muscle size in the thigh, lean body mass (the weight of everything in the body except fat), total body fat, leg strength, quality of life, and a blood marker of inflammation called C-Reactive Protein (CRP). Eight of the nine kidney disease participants and six of the eigh...
-
NCT03190694 · results posted 17 June 2024
According to the results reported on ClinicalTrials.gov, this trial involved 53 people in total (27 in one group, 26 in the other) who had kidney disease not caused by diabetes and had a certain level of protein in their urine. It was a "crossover" trial, meaning every participant took both the active tablet (dapagliflozin 10 mg) and a dummy tablet (placebo) at different times, with a six-week break in between. The trial was primarily looking at whether dapagliflozin changed the amount of protein leaking into participants' urine over 24 hours, and also tracked kidney filtration rate, blood pre...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03534284 · results posted 5 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 126 people in total across three groups: 43 received a talking-based approach called CBT-I (Cognitive Behavioural Therapy for Insomnia), 42 received a medication called trazodone, and 41 received a placebo (a dummy pill with no active ingredient). The trial was measuring insomnia and sleep-related outcomes at two points in time — around 7 weeks in (short-term) and around 25 weeks in (long-term). The main thing being measured was insomnia severity using a questionnaire called the Insomnia Severity Index, which runs fro...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04985383 · results posted 29 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04985383) enrolled 10 participants who all used a single investigational device called the AKST1210 — a type of column added to a standard kidney dialysis (haemodialysis) machine. The trial tested three different column sizes (S-15, S-25, and S-35) at two different blood-flow speeds (250 mL/min and up to 450 mL/min), with each combination used for one week. Nine of the 10 participants completed all six weeks of treatment. The trial was primarily measuring certain safety-related events, as well as how well dialysis was work...
-
NCT04696146 · results posted 29 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 people in total — 21 received a medicine called Berinert and 24 received a placebo (a dummy treatment with no active ingredient). The trial was looking at outcomes after a kidney transplant, specifically whether patients needed dialysis (a machine that does the work of the kidneys) in the first 30 days, how well the transplanted kidney was functioning at six months, and whether the transplanted kidney was still working at six months. The reported data shows that when it came to needing dialysis in the first 30 day...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03774394 · results posted 21 August 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 61 people with diabetes — 31 who also had chronic kidney disease (CKD) and 30 who did not. Two participants in the CKD group did not complete the study, so final results were based on 29 and 30 participants respectively. The trial was looking at how well a single 600 mg loading dose of clopidogrel (a blood-thinning medicine) reduced platelet reactivity — that is, how "sticky" blood platelets are — and whether having CKD alongside diabetes made any difference to that response. Platelet reactivity was measured using two...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02915601 · results posted 25 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02915601) enrolled 109 people — 55 in the sodium bicarbonate group and 54 in the placebo group. Of those, 44 and 46 people respectively completed the study. The trial was measuring changes in blood vessel function and heart-related measures in participants, specifically looking at how flexible and responsive blood vessels were, how fast pulse waves travel through the main artery (a measure of artery stiffness), and the size of the heart's main pumping chamber wall. The reported data shows the following numbers for the two...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04523220 · results posted 21 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04523220) enrolled 704 participants across three groups — a higher-dose osocimab group (234 people), a lower-dose osocimab group (235 people), and a placebo group (235 people). Osocimab is an investigational injectable medicine being studied in people with kidney disease who undergo regular dialysis. The trial was measuring two main things over six months: first, how often participants experienced significant bleeding events; and second, how often participants experienced moderate-to-severe unwanted medical events or serio...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03459807 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03459807) looked at whether it was practical to run a larger study comparing two different blood pressure targets in people on dialysis. Fifty people were screened, and 50 were enrolled — 25 in a group whose blood pressure was monitored at home (aiming for a reading below 140 mmHg), and 25 in a group whose blood pressure was measured before each dialysis session (also aiming below 140 mmHg). Almost all participants finished the study — 25 in the home monitoring group and 24 in the pre-dialysis group. The reported data sho...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03645681 · results posted 15 June 2023
According to the results reported on ClinicalTrials.gov, this trial involved 26 participants, all of whom received a device called the InnAVasc AVG — a type of artificial blood vessel graft used to create access for kidney dialysis. The trial was measuring two main things over a six-month period: how many participants' grafts remained open and usable (called "secondary patency"), and how many specific adverse events — that is, unwanted medical occurrences of particular concern — were recorded. The reported data shows that at the six-month mark, 7 out of the 12 participants who were assessed f...
-
NCT04108000 · results posted 24 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04108000) involved 38 people in total — 19 patients with dementia and end-stage kidney disease, paired with 19 "surrogates" (family members or other trusted people who would help make medical decisions on the patient's behalf). Participants were split into two groups: one received a structured conversation programme called SPIRIT-Dementia, and the other received usual care. The trial was measuring things like how well patients and their surrogates agreed on end-of-life care preferences, how much difficulty patients felt wh...
-
NCT02251431 · results posted 17 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 57 people in total — 29 received a medication called exenatide-extended release, and 28 received a placebo (an inactive dummy treatment). All 57 participants completed the study with no dropouts. The trial was measuring levels of several biological markers — substances found in blood or urine that researchers use to track things like heart stress and kidney stress. These markers were: galectin-3 and ST2 (measured in blood), and NGAL, KIM-1, L-FABP, and IL-18 (measured in urine). Each marker was compared between the ex...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03141983 · results posted 14 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03141983) enrolled 80 people on long-term kidney dialysis — 38 in the anakinra group and 42 in the placebo group. Of those, 30 and 34 respectively completed the study. The trial was measuring two main things: how often serious unwanted medical events occurred, and whether a blood marker called CRP (a protein that can rise when the body is inflamed) changed over 24 weeks of treatment. The reported data shows that serious unwanted medical events occurred at a rate of 2.71 per patient-year in the anakinra group and 2.74 per...
See all 152 reported results for Chronic Kidney Disease
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public investment in Chronic Kidney Disease research in the United States is substantial, sitting at a very large amount, and it has been growing year on year. This rising trend suggests that scientific and government bodies are increasingly prioritising this condition, which is an encouraging sign for patients hoping that new treatment options may emerge over time....
See the full Chronic Kidney Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.